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Abstract
Background: Recent Alzheimer’s disease (AD) research has focused on finding biomarkers to identify disease at the pre-
clinical stage of mild cognitive impairment (MCI), allowing treatment to be initiated before irreversible damage occurs.
Many studies have examined brain imaging or cerebrospinal fluid but there is also growing interest in blood biomarkers.
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) has generated data on 190 plasma analytes in 566 individuals with
MCI, AD or normal cognition. We conducted independent analyses of this dataset to identify plasma protein signatures
predicting pre-clinical AD.
Methods and Findings: We focused on identifying signatures that discriminate cognitively normal controls (n=54) from
individuals with MCI who subsequently progress to AD (n=163). Based on p value, apolipoprotein E (APOE) showed the
strongest difference between these groups (p=2.3610
213). We applied a multivariate approach based on combinatorial
optimization ((a,b)-k Feature Set Selection), which retains information about individual participants and maintains the
context of interrelationships between different analytes, to identify the optimal set of analytes (signature) to discriminate
these two groups. We identified 11-analyte signatures achieving values of sensitivity and specificity between 65% and 86%
for both MCI and AD groups, depending on whether APOE was included and other factors. Classification accuracy was
improved by considering ‘‘meta-features,’’ representing the difference in relative abundance of two analytes, with an 8-
meta-feature signature consistently achieving sensitivity and specificity both over 85%. Generating signatures based on
longitudinal rather than cross-sectional data further improved classification accuracy, returning sensitivities and specificities
of approximately 90%.
Conclusions: Applying these novel analysis approaches to the powerful and well-characterized ADNI dataset has identified
sets of plasma biomarkers for pre-clinical AD. While studies of independent test sets are required to validate the signatures,
these analyses provide a starting point for developing a cost-effective and minimally invasive test capable of diagnosing AD
in its pre-clinical stages.
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Alzheimer’s disease (AD) is a progressive, fatal neurodegener-
ative disorder characterized by memory loss and other cognitive
impairments. There is currently no known cure, with treatments
generally aimed at slowing disease progression. Beneficial
outcomes from treatment rely on identifying disease at its early
stages (e.g. when only mild cognitive impairment is present),
making timely, accurate forms of early diagnosis essential
(reviewed in [1–3]). As a result there has been a great deal of
recent research activity aimed at identifying diagnostic biomarkers
of pre-clinical AD.
From this research it is becoming increasingly apparent that
univariate biomarkers are not sufficiently sensitive or specific for
the diagnosis of complex, multifactorial disorders such as AD [4].
Instead researchers will need to consider applying multivariate
approaches in order to identify reliable biomarker signatures of
pre-clinical AD. The most consistent and reliable biomarkers of
AD identified to date require expensive imaging procedures or
invasive collection of cerebrospinal fluid (CSF) [5,6], whereas ideal
biomarkers would be measurable using cost-effective and mini-
mally-invasive techniques [7,8].
This has led many groups to investigate the diagnostic potential
of signatures based on protein levels in blood plasma. In 2007 a
study by Ray and colleagues, published in Nature Medicine [9],
proposed that the abundance of 18 proteins in plasma can predict
the onset of clinical AD between two and six years before the
disease clearly manifests. These proteins were identified from a
larger panel of growth factors, cytokines and other immune
response proteins. On two test sets of samples from 42 individuals
with clinical AD and 47 with mild cognitive impairment (MCI),
which can progress to AD, this 18-protein signature was able to
correctly classify 81% of AD patients and accurately predict
progression from MCI to AD in 91% of individuals assessed [9],
raising hopes that a blood-based test for AD may soon be within
reach.
Using a different mathematical approach, our group demon-
strated in 2008 that a set of only five proteins (tumor necrosis
factor-a, interleukin-1a, interleukin-3, granulocyte colony stimu-
lating factor, epidermal growth factor) from the original 18–
protein signature achieves an even better prediction accuracy
within the restricted confines of the Ray dataset, with 100%
sensitivity in predicting AD and 92% specificity in identifying
cognitively normal controls [10].
However the study of Ray and colleagues has various
limitations. Data were generated from membrane-based arrays
exposed to autoradiographic film, an assay method that is not
commonly used and has not been widely validated for quantitative
studies. In addition, the dataset that was presented in the paper
comprised Z-score transformed spot intensities rather than protein
concentration data calculated through the use of standard curves,
making it difficult to assess absolute protein signals relative to
background. Possibly as a consequence of this, other groups have
not been able to replicate the findings of original study by Ray and
colleagues [7,11,12], with several of the 18 proteins in the
signature being shown to have plasma levels below the detection
limits of other assays [12].
Recently the Alzheimer’s Disease Neuroimaging Initiative
(ADNI), a large collaborative project aimed at better understand-
ing MCI and AD, made its data available to the scientific
community. These data include various clinical, cognitive, imaging
and genetic measures, as well as the ‘Plasma Proteome Dataset’.
The Plasma Proteome Dataset, generated using a bead-based
multiplexing assay on the Luminex platform, comprises data on
levels of 190 analytes in plasma from cognitively normal controls,
individuals with MCI and AD patients. This dataset represents a
substantial improvement on the previous public domain datasets,
with a larger sample size, accessible raw data and detailed
documentation relating to the experimental procedures, quality
control measures and data analyses.
Our research group has been pioneering the use of multivariate
approaches based on combinatorial optimization to identify
molecular signatures of different diseases, including plasma protein
signatures of AD [10,13]. In contrast to routine statistical methods
that meld individual data to generate group summary values, these
approaches retain information about individual participants and
thereby also preserve the context of interrelationships between
different analytes. In this study, we have applied our analytical
approaches to the ADNI Plasma Proteome Dataset to identify
protein signatures that might be useful for the diagnosis of pre-
clinical AD.
We first consider the ability of univariate and multivariate
plasma biomarkers to distinguish between cognitively normal
controls and individuals with MCI who subsequently progress to
AD. We demonstrate that the strongest single blood biomarker
candidate on the ADNI panel, apolipoprotein E (APOE), is
influenced by genotype independent of clinical diagnosis. We also
identify an 11-analyte signature that accurately classifies partici-
pants into the correct clinical group and show that prediction
accuracy is influenced by whether or not plasma APOE levels are
taken into consideration.
We next assess the utility of biomarker signatures comprising
‘meta-features’ - functions involving two or more variables (e.g. the
relative difference in abundance of two proteins) that have recently
been shown by our group to enhance prediction accuracy in the
AD plasma protein dataset of Ray and colleagues [13]. We
demonstrate that consideration of meta-features can further
improve classification accuracy, yielding signatures with .85%
sensitivity and specificity.
We also assess the ability of plasma protein signatures to
differentiate controls from patients with diagnosed AD, as well as
to differentiate individuals with MCI who subsequently progress to
AD from those who do not. Finally, we test our proposed
signatures on data collected at a later time point, which highlights
some of the limitations of using cross-sectional data to find
biomarkers of pre-clinical AD, before going on to demonstrate
how the use of longitudinal data might inform better biomarker
selection.
Materials and Methods
ADNI Study
Data used in the preparation of this article were obtained from
the ADNI database (adni.loni.ucla.edu). Details about the ADNI
are given in the Acknowledgments section. Written informed
consent was obtained from all participants and the study was
conducted with prior institutional ethics approval. Further
information about ADNI can be obtained from www.adni-info.
org.
ADNI Dataset
The methods used in the ADNI Plasma Proteome study are
described in the document ‘Biomarkers Consortium ADNI Plasma
Targeted Proteomics Project – Data Primer’ (available at http://
adni.loni.ucla.edu).
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cognitively normal, MCI or AD based on clinical and neuropsy-
chological testing. Participants were re-classified upon follow-up
visits where appropriate. Plasma samples at baseline were collected
from 58 cognitively normal controls, 396 individuals with MCI
and 112 AD patients, selected based upon availability of additional
biomarker endpoints (e.g. CSF Ab42 levels or Pittsburgh
Compound B imaging data). Plasma samples were also collected
from a subset of these participants 12 months after baseline
assessment. Plasma samples were assayed for 190 analytes using
the ‘Human DiscoveryMAP’, developed on the Luminex xMAP
platform by Rules-Based Medicine. Of the 58 individuals classed
as cognitively normal at baseline, four have since been re-classified
as either MCI or AD and were therefore excluded from analysis.
Data Pre-Processing
Three levels of quality control were conducted for each analyte
and are described in detail in the Data Primer. Analytes which
were below assay detection limits in more than 10% of samples
were excluded by the ADNI Analysis Team (n=44). We
conducted an assessment of raw data for each of the individual
analytes that fit this criterion to ensure that undetectable samples
were not disproportionately distributed across the different disease
categories.
The ADNI dataset contains a ‘Least Detectable Dose’ (LDD)
value for each analyte. This represents the concentration of
analyte that produces a signal above the background level with
99% confidence (calculated from the average and standard
deviation of readings of at least 20 ‘blank’ replicates) and is
considered by ADNI as the most reliable lowest point for these
protein assays. In these analyses, all readings for a given analyte
below K LDD were converted to K LDD.
Where concentrations for analytes were not normally distrib-
uted, log10 transformation was applied to facilitate summary
statistics (this was required for all but nine analytes). For the initial
analyses we have considered both raw data and log10-transformed
data.
Data Grouping
Unless otherwise stated, analyses described here were conducted
on data generated from plasma samples collected at baseline. Data
generated from plasma samples collected 12 months after baseline
assessment were only used for validation studies and assessing
change in analyte levels over time. Participant samples were
separated into four groups: cognitively normal individuals
(Control), participants with MCI at baseline that have since
progressed to a diagnosis of AD (MCI Progressor), participants
with MCI at baseline that have not yet progressed to a diagnosis of
AD (MCI Other) and participants with AD at baseline (AD).
Generation of Signatures
Analyte signatures were generated based on the (a,b)-k-Feature
Set problem approach. This is a method based on techniques from
combinatorial optimization and mathematical programming. It
differs from statistical methods traditionally used in that it retains
information about individual participants within each class rather
than just considering univariate measures of class central tendency
and variance. It also has the advantage of being a multivariate
method that evaluates possible solutions involving sets of analytes,
thereby maintaining the context of interrelationships between
different analytes, which is often lost when considering each
analyte individually. Different approaches based on the (a,b)-k-
Feature Set problem, first introduced in 2004 [14], have been used to
generate molecular signatures of various diseases, notably AD and
prostate cancer [10,13,15,16].
To generate signatures for a two-class comparison (e.g. Control
vs. MCI Progressor) using this approach, the data are first
preprocessed by filtering and discretization of the values. (An
example is given below under ‘Classification – Univariate
Markers’.) An implementation of Fayyad and Irani’s algorithm
[17], an entropy-based heuristic, is used to discretize data. This
approach identifies, for each analyte, the concentration threshold
with minimal class information entropy (a measure of how well a
threshold separates the two classes) and discretizes the data based
on this threshold. It then discards analytes that do not provide
sufficient information to discriminate between the two classes
under consideration, based on the Minimum Description Length
principle (reviewed in [18]). This results in a dataset of binary
values (representing analyte concentrations above or below the
concentration threshold). By using binary data, the analysis results
are not skewed by outlying values, as can occur with standard
statistical approaches that compare group means.
The matrix of discrete values returned after entropy filtering is
used to create an instance of the (a,b)-k-Feature Set problem. This
models the problem of identifying a set of features (i.e. analytes,
now discretized) that have maximum internal consistency in both
distinguishing different sample classes (e.g. ‘health states’) and
showing similarity within each sample class [18].
For each pair-wise grouping of samples in the dataset, the (a,b)-
k-Feature Set problem considers the capacity of each feature (e.g.
analyte) to describe the class labels (e.g. Control, MCI Progressor)
of the two samples comprising this pair, based on the discrete
values of a given feature for the samples in question. For example,
when considering a pair comprising samples from different classes
(e.g. one Control participant and one MCI Progressor participant),
a given feature would be able to describe the class labels if its
discrete values differed between the two samples. On the other
hand, when considering a pair comprising samples from the same
class (e.g. two Control participants), a given feature would be able
to describe the class labels if its discrete values were the same in
both samples.
The (a,b)-k-Feature Set problem involves three parameters; a,
defined as the minimum number of features that must discriminate
between any pair of samples from different classes; b, defined as
the minimum number of features that must have the same discrete
value for any pair of samples from the same class; and k, defined as
the number of features (analytes) in the solution. In the present
study, we have defined the optimal solution as one that achieves
the minimal value for k with a=1 and b=1. In the case that more
than one solution satisfies these conditions, we select the solution
that provides the greatest ‘coverage’ of sample pairs belonging to
different classes (we refer to [18] for details of this method). This
approach has been applied previously by our group for feature
selection in another AD plasma protein dataset [10,13] and in a
study of hippocampal gene expression in AD [15], as well as
investigations of other diseases [16].
Heat maps
Heat maps were generated by ordering analytes and samples
using a high performance Memetic Algorithm. This technique is
described elsewhere [18,19] but briefly, it aims to minimize an
objective function, in this case the correlation distance (where
correlation distance=12correlation coefficient), both between
different analytes and between different samples. This is achieved
by applying an evolutionary approach, thereby improving upon
the single-pass hierarchical clustering techniques that have been
traditionally used for ordering large datasets [18,19]. The solution
ADNI Plasma Biomarkers of Alzheimer’s Disease
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of rectangles colored along a green-red continuum (‘heat map’),
with green representing lower expression values and red
representing higher expression values.
Classification
By determining which individual analytes pass the entropy filter
and which set of analytes provide an optimal solution to the (a,b)-
k-Feature Set problem, we can identify potential biomarkers that
discriminate between two health states. However this process does
not in itself directly provide a rule or formula that specifies in
which health state an individual having particular values for the
selected analytes should be classified. Instead, the potential utility
of individual analytes or sets of analytes for classifying individuals
into the correct health state was assessed as follows.
Univariate Markers. Analytes that passed the entropy filter
(described above) were ranked by their ability, based on the binary
values assigned in the discretization preprocessing step, to classify
samples into the correct class (e.g. Control or MCI Progressor). As
a hypothetical example, when comparing controls and MCI
progressors, assume that for ‘analyte X’ the concentration
threshold selected based on class information entropy is 50. All
samples with an ‘analyte X’ concentration below this threshold are
assigned a value of 0 and all samples above this threshold assigned
a value of 1. We determine the percentage of control samples
assigned a value of 0 for ‘analyte X’ and the percentage of MCI
progressor samples assigned a value of 1, and vice versa. This
process is repeated for all analytes that passed the entropy filter.
Multivariate Signatures. Classification of participants into
one of two classes or ‘health states’ (e.g. Control or MCI
Progressor) based on plasma levels of multiple analytes was
performed using a number of different classification algorithms
available in the Waikato Environment for Knowledge Analysis
(WEKA) package [20]. The WEKA package contains 70 classifiers
derived from different machine learning approaches (e.g. Bayes-
based, tree-based, rules-based etc). We assessed the performance of
each of the classifiers within the WEKA package across nine
different signatures and selected 10 that consistently gave the
highest Matthews Correlation Coefficient (see below) using a cross-
validation approach (Table S1). These 10 classifiers subsequently
used to test the ability of the different signatures to correctly
classify participants into one of two health states. Results presented
in this paper are the average of the data from the 10 different
classifiers. (We note that after the analytes that comprise a
particular signature have been identified, the discretized values are
no longer used and instead we use the original values for the
creation of classifiers.)
For classifications in which only one dataset was used, a 10-fold
cross-validation was conducted. This widely used approach
involves randomly dividing the sample set into 10 subsets. The
classifier then uses nine of these subsets as training data and one as
a test set. This process is repeated 10 times, so that each of the 10
subsets is used exactly once as the test set. The results are then
combined to give a single measure of sensitivity (proportion of
affected participants correctly assigned to the disease class – true
positives) and specificity (proportion of non-affected participants
correctly assigned to the control class – true negatives) for the
given signature (Figure 1a). As the size of the control group was
substantially smaller than that of the MCI or AD groups when
considering all samples, we also calculated the Matthews
correlation coefficient (MCC; Figure 1b). This approach is
recommended for binary data when class numbers are unequal
and is preferred to simpler approaches, such as the average of the
sensitivity and specificity, as it preserves information about all four
components of the contingency matrix (Figure 1a) in an unbiased
way [21].
There are presently no other publicly available datasets that are
suitable for testing the signatures we have developed here. Instead,
we also assessed the classification accuracy of the signatures using
an artificial training/test set approach, in which samples from each
health state were divided equally into one training set and one test
set. The training and test set were matched for age, gender and
APOE genotype but otherwise randomly assigned. Due to the
disproportionate sizes of the different classes, we created single
additional size-matched groups (e.g. 54 controls and 54 MCI
progressors) that were age- and gender-matched but otherwise
randomly assigned. For the small number of analyses where size-
matched training and test sets were required, these groups were
further sub-divided in one training set and one test set (e.g. n=27
controls, 27 MCI progressors per set) that were also age- and
gender-matched but otherwise randomly assigned.
Additionally, we assessed some of our proposed signatures on
ADNI data from plasma samples collected 12 months after
baseline assessment. These samples were collected from a subset of
participants from the larger baseline group described above. This
subset consisted of 50 controls, 92 MCI progressors and 97 AD
patients.
Results
Demographics
The demographics of the sample at baseline are given in
Table 1. (The demographics of the subset of participants for whom
12 month data were collected mirrored those of the larger cohort.)
Age did not vary significantly between the different groups (p-
value=0.96, one-way ANOVA). The MCI and AD groups had a
higher proportion of males to females than controls. Frequency of
the APOE-e4 allele, the main genetic risk factor for late-onset
Alzheimer’s disease [22,23], was substantially higher in MCI and
AD patients than controls. Mini-Mental State Examination
(MMSE) score differed significantly between all groups (p,0.01),
with Control.MCI Other.MCI Progressor.AD.
Figure 1. Calculation of Matthews Correlation Coefficient (MCC). (A) Contingency matrix illustrating our usage of true negatives (TN), false
positives (FP), false negatives (FN) and true positives (TP). (B) Mathematical definition of the MCC.
doi:10.1371/journal.pone.0034341.g001
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colleagues
A highly-cited study by Ray and colleagues [9] generated a
dataset of relative plasma protein levels in cognitively normal
controls, individuals with MCI and AD patients and reported an
18-protein biomarker signature for distinguishing controls from
AD patients. We have previously applied our analytical methods
to the dataset contributed by Ray and colleagues [9], refining their
18-protein biomarker signature to a 5-protein signature [10] as
well as identifying sets of protein pairs (i.e. the difference in relative
abundance of two proteins) that can also accurately classify these
participants [13].
However the study of Ray and colleagues did not provide data
on the absolute plasma levels of the different proteins assessed. We
checked the proteins highlighted by Ray and colleagues in the
ADNI dataset to gauge their level in plasma. Of the 18 proteins in
the signature of Ray and colleagues [9], four were not included in
the ADNI assay and three of the remaining 14 assessed by ADNI
were below the detection limit of the Luminex assay (Figure 2,
Table S2) – interleukin-1a, interleukin-11 and granulocyte colony
stimulating factor. (Two of the five proteins in our reported
signature based on the Ray dataset [10], as well as two of six
proteins highlighted in our analysis of protein pairs from the Ray
dataset [13], were also below the detection limit of the ADNI
assay.)
Control vs. MCI Progressor
One of the main questions driving this study was whether there
exists a signature of plasma analytes that can successfully predict
AD progression in pre-clinical participants and also distinguish
these individuals from controls who do not progress to cognitive
impairment (at least in the short term). For this reason we focused
our attention on comparing baseline plasma analyte levels in
cognitively normal controls who do not proceed to cognitive
impairment (n=54) with participants classified as MCI at baseline
who have since been reclassified as AD (‘MCI Progressor’;
n=163).
Univariate analysis. Univariate statistical analysis identified
APOE as the analyte differing most significantly between controls
and MCI progressors, with lower levels in plasma from MCI
progressors than controls. In statistical comparisons of the two
groups (two-tailed t-test, adjusted using Welch’s correction where
appropriate), APOE returned the lowest p value (2.3610
213) of all
analytes assessed (Table S3). Only two analytes from the 18-
protein signature reported by Ray and colleagues (Figure 2)
showed statistically significant differences in the ADNI dataset -
angiopoietin-2 and pulmonary and activation regulated
chemokine.
We next applied a filtering step based on class information
entropy (details in Methods) to eliminate analytes that did not
provide good discrimination of control and MCI progressor
samples. Of the 146 analytes considered detectable, 17 passed the
entropy filter. These analytes were ranked by their ability, based
on discrete values assigned by the entropy filter, to classify control
and MCI progressor samples correctly (as described in Methods).
Using this metric, APOE was again the analyte whose levels best
discriminated the two groups based on MCC (Table 2). None of
the analytes in the 18-protein signature reported by Ray and
colleagues (Figure 2) passed the entropy filter.
Effect of APOE genotype on APOE plasma levels. While
these analyses suggest that plasma levels of APOE are a good
marker of pre-clinical AD, it is possible that these results may be
influenced by effects of APOE genotype, which modifies AD risk
[22–26] and may also influence cognitive performance in non-
demented individuals [27–30]. We therefore investigated whether
APOE genotype can influence plasma APOE levels independent of
clinical diagnosis.
Plasma levels of APOE differed significantly with APOE
genotype independent of clinical diagnosis (as assessed by one-
way ANOVA with Tukey’s multiple comparison test), with a
progressive decrease in plasma APOE from ‘protective’ genotypes
(e2) to ‘at risk’ genotypes (e4; Figure 3). In view of this finding, all
subsequent analyses were conducted on two sets of data - one that
included the plasma APOE analyte and one that excluded the
APOE analyte. (This is not to be confused with analyses that
exclude participants with a particular APOE genotype.)
Figure 2. Detectability in the ADNI dataset of the 18 proteins
highlighted by Ray et al. (2007). Of the 18 proteins in the signature
highlighted by Ray and colleagues [9], three were below the detection
limits of the ADNI assay, 11 were considered detectable by ADNI and
four were not assessed. Protein abbreviations are defined in Table S2.
doi:10.1371/journal.pone.0034341.g002
Table 1. Baseline demographics.
Control MCI AD
Other Progressor
N Plasma
samples
54 233 163 112
Mean age
(range)
75.4 (62–90) 75.0 (55–90) 74.8 (55–89) 75.4 (55–89)
Gender M/F 27/27 157/76 99/64 65/47
APOE-e4
frequency
9% 43% 67% 68%
Mean MMSE
score (range)
28.9 (25–30) 27.3 (24–30) 26.6 (23–30) 23.6 (20–27)
doi:10.1371/journal.pone.0034341.t001
ADNI Plasma Biomarkers of Alzheimer’s Disease
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e34341Table 2. Accuracy of the analytes that passed entropy filtering in classifying control and MCI progressor samples.
Analyte % Controls Correct (number) % MCI Progressor Correct (number) MCC
Apolipoprotein E 79.6 (43) 74.8 (122) 0.484
Apolipoprotein A-II 88.9 (48) 55.2 (90) 0.384
Macrophage Inflammatory Protein-1a 35.2 (19) 93.9 (153) 0.369
Eotaxin-3 16.7 (9) 100.0 (163) 0.361
Transthyretin 59.3 (32) 78.5 (128) 0.354
Brain Natriuretic Peptide 48.1 (26) 85.3 (139) 0.343
Heparin-Binding EGF-Like Growth Factor 64.8 (35) 71.2 (116) 0.321
a2-Macroglobulin 35.2 (19) 91.4 (149) 0.320
Calcitonin 48.1 (26) 82.8 (135) 0.310
Peptide YY 22.2 (12) 96.9 (158) 0.308
Betacellulin 72.2 (39) 63.2 (103) 0.307
Serotransferrin 53.7 (29) 77.9 (127) 0.298
C-Reactive Protein 55.6 (30) 76.1 (124) 0.294
Serum Glutamic Oxaloacetic Transaminase 85.2 (46) 47.2 (77) 0.287
Angiotensinogen 87.0 (47) 43.6 (71) 0.276
Fas Ligand 87.0 (47) 41.7 (68) 0.261
CD5 100.0 (54) 19.6 (32) 0.239
Analytes ordered by Matthews correlation coefficient (MCC). Control n=54, MCI Progressor n=163.
doi:10.1371/journal.pone.0034341.t002
Figure 3. APOE plasma concentration as a function of APOE genotype. APOE concentration shows a decreasing trend from ‘protective’ (e2)
to ‘at risk’ (e4) genotypes that is independent of clinical diagnosis. Plots illustrate APOE log10 plasma concentrations as a function of APOE genotype
when considering samples classified at baseline as (A) control (n=54), (B) MCI (n=396) and (C) AD (n=112). Plot (D) illustrates the trend when
baseline diagnosis is not considered. 2/3 – APOE-e2/e3; 2/4 – APOE-e2/e4; 3/3 - APOE-e3/e3; 3/4 - APOE-e3/e4; 4/4 - APOE-e4/e4. Statistically significant
(p,0.05) difference when compared to
a2/3,
b2/4,
c3/3,
d3/4. Statistical tests were not conducted on sample sets of n,4.
doi:10.1371/journal.pone.0034341.g003
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method, based on finding the smallest solution to the (a, b)-k-
Feature Set problem (Methods), to identify a set of analytes (signature)
that together best discriminate control samples from MCI
progressor samples. The signature that has the smallest number
of analytes and is a solution to the feature set problem (for a=1
and b=1 and maximum coverage) contains 11 analytes (Table 3,
Figure S1a). No solution was possible when the APOE analyte was
excluded from consideration (i.e. not every sample pair could be
described or ‘covered’ by at least one analyte). Nonetheless, to
determine whether a signature without APOE can still be useful
for classifying most participants, we generated the optimal set (the
highest possible values for a and b and greatest ‘coverage’) when
constraining the size of the signature to 11 analytes (Table 3,
Figure S1b). Identical signatures are obtained for both log10-
transformed data and raw data.
The ability of these signatures to correctly classify the full set of
controls and MCI progressors was assessed with the WEKA
package using both a 10-fold cross-validation approach and an
artificial training/test set approach (Methods). Using each of 10
different classifiers based on various different machine learning
models (Table S1), the signature containing the APOE analyte
achieved an average sensitivity of over 90% but a specificity of less
that 70%. The signature excluding the APOE analyte had a
comparable sensitivity but an even lower specificity (Table 4).
As the use of raw data resulted in identical signatures and
comparable classification accuracy to log10-transformed data, all
further analyses were conducted on log10-transformed data only,
which have a normal distribution and could therefore be used for
Z-score transformation for heat maps and consideration of analyte
pairs (below).
Influence of group size on measures of sensitivity and
specificity. As described above, when tested within the various
classifiers on the unequal Control and MCI Progressor groups
(where there were three times as many MCI progressors as
controls), the multivariate signatures returned low values for
specificity (i.e. accuracy in correctly classifying controls) relative to
sensitivity (i.e. accuracy in correctly classifying MCI progressors).
This would be problematic in a clinical setting, where it is
important not to misdiagnose healthy individuals as having an
incurable, terminal condition.
We hypothesized that the discrepancy observed between values
for sensitivity and specificity (irrespective of whichever classifier
was used) was an artefact of having disproportionately sized
groups, as classification algorithms in general apply strategies that
optimize total accuracy (i.e. in this case, the total number of
correctly called controls and MCI progressors). This biases correct
classification towards groups with larger sample size, as is the case
here for MCI progressors. To determine the effect of group size on
tuning the classification strategies and subsequent values for
sensitivity and specificity, we tested our signatures on size-matched
groups of MCI progressors and controls (n=54 per group). In
most tests, matching of group sizes gave sensitivity and specificity
results that were less discrepant than when considering the full set
of samples. Across the different classification approaches, sensitiv-
ity and specificity were generally in the range of 65–85% (Table 4).
To evaluate the effectiveness of our feature selection method
relative to selection strategies based on statistical measures, we
assessed the classification accuracy of a signature comprising the
11 analytes showing the most statistically significant differences
between controls and MCI progressors. Our signature out-
performed the statistics-based signature in all classification tests
performed (Table 4). We also assessed whether using the full set of
available plasma analyte data provided more accurate classifica-
tion than our 11-analyte signature. As expected, using data on all
146 analytes gave highly accurate classification on a training set,
however it resulted in a poorer performance (based on MCC)
when assessed by cross-validation or applied to test sets (Table 4),
probably due to overfitting of the data.
We also generated new signatures using the size-matched
dataset of 54 controls and 54 MCI progressors. A total of 11
analytes passed the entropy filter (Table S4), all of which were
identified when considering the full set of samples with the
exception of Tamm-Horsfall Urinary Glycoprotein. Classification
of control and MCI progressor samples within the size-matched
dataset gave a sensitivity and specificity comparable to those
obtained when assessing the original signatures (Table S5).
Table 3. Feature set selection of 11-analyte signatures to discriminate control and MCI progressor samples.
Analyte (abbreviation)
a) Including APOE b) Excluding APOE
*a2-Macroglobulin (a2M) *a2-Macroglobulin
Angiotensinogen Angiotensinogen
Apolipoprotein A-II (ApoA-II) Apolipoprotein A-II
Apolipoprotein E (ApoE) Brain Natriuretic Peptide (BNP)
*Betacellulin (BTC) CD5
Fas Ligand (FasL) Eotaxin-3
Heparin-Binding EGF-Like Growth Factor (HB-EGF) Heparin-Binding EGF-Like Growth Factor
Macrophage Inflammatory Protein-1a (MIP-1a) Macrophage Inflammatory Protein-1a
Peptide YY (PYY) Peptide YY
*Serum Glutamic Oxaloacetic Transaminase (SGOT) *Serotransferrin (Tf)
Transthyretin (TTR) Transthyretin
Signatures were generated using baseline data on 54 Control and 163 MCI Progressor participants. Analytes in italics were selected in both signatures (i.e. independent
of the inclusion/exclusion of APOE).
*Analytes that passed the entropy filter and were selected in the signature but did not show statistically significant (p,0.01) differences between controls and MCI
progressors (Table S3).
doi:10.1371/journal.pone.0034341.t003
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sensitivity and specificity. Age and gender are known to
influence the levels of particular blood proteins and, while the
Control and MCI Progressor groups were matched for both age
and gender, it is possible that the accuracy of the proposed
signatures in correctly classifying individuals from these two
groups may vary depending on age and gender. To investigate this
possibility, we stratified the size-matched groups into subsets
containing exclusively male or female participants (n=27 for each
gender) and subsets stratified as ‘younger’ or ‘older’ participants
(based on the median age of each group). Classification using a 10-
fold cross-validation approach showed no discernible difference
between measures of sensitivity and specificity when signatures
were applied to male and female groups separately. In
comparisons of the ‘younger’ and ‘older’ subsets, the signature
containing the APOE analyte performed slightly better in
classifying participants in the ‘older’ subset i.e. above the median
age (Table S6), however neither signature performed better on
age-stratified subsets than on the larger non-stratified group.
Because of the potential confounding effect of APOE genotype,
we also considered a restricted sample that included only
individuals with homozygous APOE-e3 genotypes (34 controls,
50 MCI progressors). In this restricted group, APOE no longer
passed the entropy filter of analytes discriminating between
controls and MCI progressors (Table S7, Figure S2). Of the six
analytes passing the entropy filter, all but one (a1-antitrypsin) were
previously identified when considering the full set of samples,
suggesting that these markers are robust against the influence of
APOE genotype. This set of six analytes was able to classify APOE-
e3 homozygote controls and MCI progressors with an average
sensitivity of 83.6% and a specificity of 77.6% (MCC=0.61).
Finally, as age, gender and APOE genotype are all known to
influence risk of AD, we assessed the ability of these three
attributes, as a collective, to discriminate controls from MCI
progressors. Using a ‘signature’ comprising these three variables,
classification of a size-matched dataset of Control and MCI
Progressor participants achieved a sensitivity of 71% and a
specificity of 80%. This was largely driven by APOE genotype
(which alone gives an accuracy of almost 80%) rather than age or
gender.
Meta-feature analysis
Our group has previously demonstrated that incorporating
‘meta-features’ into biomarker signatures can improve classifica-
tion accuracy [13]. A meta-feature can be considered as any
function that involves more than one feature, such as the
difference in abundance of two analytes. Here and in the previous
study [13], for simplicity, we only consider meta-features based on
two variables and a simple arithmetic function. This is a
generalization of a common practice in classification. For instance,
consideration of the ratio of concentrations of two different
analytes has already been used to successfully establish CSF
biomarkers of AD from univariate analysis (e.g. Ab42/tau) [31,32].
Using meta-features based on concentration ratios for biomarker
discovery can help mitigate any confounding effects due to inter-
sample biological variability or technical variability (e.g. differ-
ences in the volume of sample assayed), as the two analytes are
jointly measured and their concentrations relative to one another
determined within each individual sample. The use of meta-
features can also facilitate the identification of features that are
mathematically or biologically dependent in a supra-additive
(synergistic) way with regard to disease prediction capacity i.e.
potentially inter-related (whether directly or not). We therefore
calculated differences and sums of Z-score values for each possible
analyte pair, which is equivalent to calculating the ratio and
product of the relative abundance of two analytes.
Pair-wise differences. When considering differences in Z-
scores of analyte pairs for controls against MCI progressors, 1,141
meta-features passed the entropy filter from a total of 10,585. As
described above for single analyte analysis, each meta-feature
passing the entropy filter was assessed for its ability, based on
discrete values assigned by the entropy filter, to classify control and
Table 4. Accuracy of analyte signatures in classifying controls and MCI progressors.
Signature Cross-Validation Training Set Test Set
Sens Spec MCC Sens Spec MCC Sens Spec MCC
Signature with APOE
aFull set of samples 93.5 66.9 0.64 97.8 93.7 0.92 93.0 64.8 0.61
bSize-matched groups 74.3 79.3 0.54 97.8 93.7 0.92 85.9 64.8 0.52
Signature without APOE
Full set of samples 92.0 54.3 0.50 97.7 85.6 0.86 91.6 46.3 0.43
Size-matched groups 67.2 73.5 0.41 91.1 96.3 0.88 77.0 71.1 0.50
Top 11 analytes - p val
Full set of samples 91.3 60.0 0.54 96.8 90.7 0.88 91.5 56.3 0.51
Size-matched groups 70.2 70.6 0.41 90.7 94.8 0.86 84.4 64.4 0.51
All 146 analytes
Full set of samples 94.0 57.4 0.57 99.4 97.8 0.97 95.1 53.3 0.55
Size-matched groups 69.1 73.5 0.43 98.9 99.3 0.98 71.5 70.7 0.42
Classification accuracy was tested using log10-transformed data. We have used bold font to draw particular attention to the signatures with the best performance (as
assessed by MCC) in each comparison (i.e. 10-fold cross-validation, training set or test set). As expected, using all 146 analytes leads to some overfitting on the training
set but our signatures that include the APOE analyte perform better in test scenarios.
aThe full set of samples contained data on 54 Controls and 163 MCI Progressors.
bThe size-matched groups contained data on 54 Controls and 54 MCI Progressors. For each of these datasets, all samples were used for cross-validation, whereas
training and test sets were created by dividing datasets into two equal subsets.
doi:10.1371/journal.pone.0034341.t004
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ordered based on this metric and the top 100 ranked meta-
features were used to generate a signature. (Generating a signature
from the full set of meta-features passing the entropy filter was not
computationally feasible.) When APOE-related meta-features
were included, the smallest signature that produced a solution to
the feature set problem (with a=1 and b=1 and maximum
coverage) contained 8 meta-features (3 of which involved APOE)
and involved 13 different analytes. When APOE was excluded
from consideration, the smallest signature that produced a solution
contained 7 meta-features, which also involved 13 different
analytes (Table 5, Figure S3). The smaller size of the signature
when APOE-related meta-features were excluded is probably due
to the dominance of APOE among the top 100 ranked meta-
features passing the entropy filter. When the APOE-related meta-
features were removed from consideration, a large number of new
meta-features were introduced into the top 100 list – these in turn
contributed to a new solution that required less meta-features.
These meta-feature signatures achieved higher classification
accuracy than the signatures involving single analytes described
above. In addition, the exclusion of APOE-related meta-features
from the signature did not profoundly affect prediction accuracy.
When considering the size-matched groups of controls and MCI
progressors, the signatures containing pair-wise differences
achieved a sensitivity and specificity of greater than 85%,
irrespective of the classification approach used (Table 6).
To ensure that the improved performance of meta-feature
signatures was not solely the result of using 13 different analytes
rather than 11 (the number comprising single analyte signatures
above), we used the (a,b)-k-Feature Set problem approach to
determine the optimal solution containing 13 single analytes, as
well as creating a signature comprising the 13 analytes showing the
most statistically significant differences between controls and MCI
progressors. In all classification tests conducted, the meta-feature
signatures correctly classified a higher proportion of both controls
and MCI progressors than the single analyte signatures (Table S8),
suggesting that consideration of meta-features can be a valuable
tool to supplement more traditional approaches to biomarker
discovery.
Pair-wise sums. We also considered the utility of meta-
features involving pair-wise sums. A total of 980 meta-features
passed the entropy filter, of which 8 were required to produce a
solution to the feature set problem (Table S9, Figure S4). Unlike
the signatures comprising pair-wise differences discussed above,
the consideration of pair-wise sums did not result in markedly
improved classification accuracy when compared to signatures
containing single analytes (Table S10).
Summary of prediction accuracy of different signatures
In summary, the multivariate plasma analyte signatures
identified here effectively discriminated a high proportion of
MCI progressors from cognitively normal controls. When the
signatures were tested on the full set of participants, biases in the
classification algorithms led to the correct classification of a high
proportion of MCI progressors but a relatively low proportion of
controls. Tuning the classification algorithms on size-matched
control and MCI progressor groups, although resulting in a
reduction in MCC values, mostly eliminated the disparity between
values for sensitivity and specificity that occurred when classifying
groups of disproportionate sizes. Relative to signatures comprising
sets of single analytes, consideration of pair-wise differences
generally resulted in a further improvement in sensitivity and
specificity, particularly for signatures in which APOE-related
features were excluded, whereas consideration of pair-wise sums
had little effect.
Control vs. AD
Similar to comparisons of controls and MCI progressors above,
univariate statistical analysis revealed APOE as the analyte
differing most significantly between controls and AD patients,
with lower levels in plasma from AD patients relative to controls.
In statistical comparisons of the two groups (two-tailed t-test,
adjusted using Welch’s correction were appropriate), APOE
returned the lowest p-value (5.2610
27) of all analytes assessed
(Table S11).
The multivariate signatures comprising single analytes that were
generated when comparing control and MCI progressor groups
were applied to data from AD samples to determine the accuracy
of these signatures in classifying AD patients. The set of 10
classifiers were trained on sized-matched sets of controls and MCI
progressors and then tested on the full set of AD patients (n=112).
The signature containing APOE accurately predicted AD in
Table 5. Minimal meta-feature set selection of differences in analyte abundances to discriminate Control and MCI Progressor
samples.
Analyte pairs (abbreviation)
a) Including APOE b) Excluding APOE
Angiopoietin-2 & Interleukin-16 (ANG-2 – IL-16) a1-Microglobulin & Apolipoprotein A-II (a1M – ApoA-II)
Apolipoprotein A-II & Betacellulin (ApoA-II – BTC) Angiopoietin-2 & Neuronal Cell Adhesion Molecule (ANG-2 – Nr-CAM)
Apolipoprotein E & Brain Natriuretic Peptide (ApoE – BNP) Angiopoietin-2 & Transthyretin (ANG-2 – TTR)
Apolipoprotein E & Serotransferrin (ApoE – Tf) Apolipoprotein D & Insulin-like Growth Factor-Binding Protein 2 (ApoD – IGFBP-2)
Apolipoprotein E & Thrombopoietin (ApoE – Thrombopoietin) C-Reactive Protein & Pregnancy-Associated Plasma Protein A (CRP – PAPP-A)
Chromogranin-A & Heparin-Binding EGF-Like Growth Factor (CgA – HB-EGF) Macrophage Inflammatory Protein-1a & Pulmonary and Activation-Regulated
Chemokine (MIP-1a – PARC)
Interleukin-6 receptor & Macrophage Inflammatory Protein-1a (IL-6r – MIP-1a) Matrix Metalloproteinase-10 & Matrix Metalloproteinase-9 (MMP-10 – MMP-9)
Macrophage Inflammatory Protein-1a & Pulmonary and Activation-Regulated
Chemokine (MIP-1a – PARC)
Signatures were generated using baseline data on 54 Control and 163 MCI Progressor participants. Meta-features in italics contain at least one analyte identified in the
corresponding signature generated by single analyte analysis (Table 3).
doi:10.1371/journal.pone.0034341.t005
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predicted 65.9%. Not surprisingly, when classifiers were trained on
the full set of controls and MCI progressors (which biases
classification towards higher sensitivity), the accuracy of predicting
AD improved substantially. The signature including APOE
accurately predicted AD in 79.2% of patients, while the signature
excluding APOE accurately predicted 85.2%. As APOE showed
such a strong difference between controls and AD patients, it may
seem surprising that the signature with APOE correctly classified a
lower percentage of AD patients than the signature without
APOE. This may be due to the latter signature containing other
analytes that better discriminate between control and AD than
those included in the APOE-containing signature, for example
eotaxin-3, which, as discussed below, best discriminated the
control and AD groups based on MCC (Table 7).
We next looked at whether a different set of analytes might
better discriminate between controls and AD patients than the sets
previously determined from comparisons of the control and MCI
progressor groups. To assess this, we compared baseline plasma
analyte levels in cognitively normal controls who did not proceed
to cognitive impairment with those in patients classified as AD at
baseline.
Of the 146 analytes considered detectable, 13 passed the
entropy filter. As described in Methods, these analytes were ranked
by their ability, based on discretized values assigned by the entropy
filter, to classify AD and control samples correctly (Table 7). Using
this metric, as mentioned above, eotaxin-3 best discriminated the
two groups based on MCC. However the findings suggest that
assessing eotaxin-3 alone would result in misclassifying a
substantial proportion of healthy controls, which, as noted above,
would be generally considered unacceptable in a clinical setting.
Instead it might be preferable to trade sensitivity for specificity and
select a marker that can correctly classify a higher percentage of
controls, such as serum glutamic oxaloacetic transaminase.
The smallest signature that produced a solution (i.e. a=1,b=1)
to the feature set problem contained 11 analytes or, when the
APOE analyte was excluded, 12 analytes (Table S12, Figure S5).
While these signatures showed some similarities to the signatures
selected above for discriminating controls and MCI progressors
(shaded in Table S12), there were several differences. These
Table 7. Accuracy of the analytes that passed entropy filtering in classifying control and AD samples.
Analyte % Controls Correct (number) % AD Correct (number) MCC
Eotaxin-3 63.0 (34) 80.4 (90) 0.429
Brain Natriuretic Peptide 48.1 (26) 88.4 (99) 0.404
Serum Glutamic Oxaloacetic Transaminase 85.2 (46) 54.5 (61) 0.377
Apolipoprotein E 79.6 (43) 58.0 (65) 0.354
a1-Microglobulin 75.9 (41) 61.6 (69) 0.352
Betacellulin 83.3 (45) 53.6 (60) 0.351
Apolipoprotein A-II 88.9 (48) 46.4 (52) 0.347
Pregnancy-Associated Plasma Protein A 87.0 (47) 48.2 (54) 0.343
Peptide YY 85.2 (46) 50.0 (52) 0.339
Placenta Growth Factor 100 (54) 25.0 (28) 0.313
Receptor for Advanced Glycosylation End
Product
90.7 (49) 39.3 (44) 0.308
CD5 100 (54) 20.5 (23) 0.278
Immunoglobulin M 100 (54) 15.2 (17) 0.235
Analytes ordered by Matthews correlation coefficient (MCC). Control n=54,ADn=112.
doi:10.1371/journal.pone.0034341.t007
Table 6. Accuracy of meta-feature signatures involving differences in analyte abundances in classifying controls and MCI
progressors.
Signature Cross-Validation Training Set Test Set
Sens Spec MCC Sens Spec MCC Sens Spec MCC
8-metafeature signature with APOE
aFull set of samples 94.7 78.1 0.74 99.1 96.3 0.96 93.2 64.8 0.61
bSize-matched groups 90.2 87.2 0.77 98.9 98.1 0.97 85.6 86.7 0.73
7-metafeature signature without APOE
Full set of samples 95.6 78.1 0.76 97.9 95.9 0.93 96.0 72.6 0.73
Size-matched groups 83.3 87.6 0.71 90.7 99.2 0.91 90.7 83.0 0.74
aThe full set of samples contained data on 54 Controls and 163 MCI Progressors.
bThe size-matched groups contained data on 54 Controls and 54 MCI Progressors. For each of these datasets, all samples were used for cross-validation, whereas
training and test sets were created by dividing datasets into two equal subsets.
doi:10.1371/journal.pone.0034341.t006
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less than 65% when assessed on the full set of control and AD
samples. When assessed on size-matched groups, sensitivity and
specificity were more comparable but still relatively low (less than
75%; Table S13). These values are lower than those achieved
when using multivariate signatures to classify controls and MCI
progressors, possibly due to the lower number of samples in the
AD group relative to the MCI Progressor group.
We also investigated whether the signatures generated by
comparing controls and AD patients could effectively discriminate
controls from MCI progressors. When tested on size-matched
groups of controls and MCI progressors, the signature containing
the APOE analyte returned a sensitivity of 67% and specificity of
76%, while the signature excluding APOE returned the same
sensitivity but a lower specificity (66%). These values were
considerably lower than those achieved by signatures derived
from direct comparison of the Control and MCI Progressor groups
(Table 4).
MCI Progressor vs. MCI Other
In addition to biomarker signatures that can distinguish healthy
controls from pre-clinical and clinical AD patients, it would be
informative to be able to discriminate MCI patients who are likely
to progress to AD from those who are not. We therefore attempted
to generate a signature when comparing participants with MCI at
baseline who have since progressed to AD (MCI Progressor;
n=163) and participants with MCI at baseline who have not yet
progressed to AD (MCI Other; n=233). Statistical comparisons of
the two groups by t-test revealed 9 analytes that differed
significantly in their levels (p,0.05, unadjusted for multiple
testing; Table S14). Of these, macrophage inflammatory protein-
3a had the lowest p-value (0.0015). However none of the analytes
had sufficient discriminatory power to pass the entropy filter. As
discussed further below, the lack of strong discriminators in this
comparison may be due to heterogeneity within the MCI Other
group, where some participants may progress to AD in the future,
some may progress to different dementias and others may remain
with MCI or even revert to control status.
To reduce heterogeneity within the MCI Other sample, we
excluded participants who were re-classified as cognitively normal
controls at one of the clinical follow-up visits (n=19), however
there were still no analytes that passed the entropy filter.
Validation of signatures using data from 12 month
follow-up
For a number of participants assessed at baseline, plasma
analyte concentrations were also measured during a follow-up visit
12 months later. For clinical utility, ideally a signature should be
robust both against technical variation and against biological
variation which is unrelated to the condition of interest. To
evaluate the broader applicability of the previously derived
signatures, we assessed the classification accuracy of these
signatures on plasma protein data obtained from participants at
12 months follow-up.
Control vs. MCI Progressor. For the participants used in
the baseline analysis described above, 12 month data were
available for 50 controls and 92 MCI progressors (all MCI
progressors who had converted to AD in the period between
baseline and 12 month evaluations were excluded from analysis).
When the previous signatures were used to classify participants
based on the data at 12 months, the sensitivity and specificity were
low compared to the sensitivity and specificity achieved by these
same signatures on the baseline data, for both the full set of
participants and size-matched groups (Table 8).
We next applied the meta-feature signatures involving the
difference in relative levels of pairs of analytes to the 12 month
data. As for the single analyte signatures, the meta-feature
signatures were not effective in discriminating controls and MCI
progressors in the 12 month data (Table 8).
Control vs. AD. In addition, we assessed the classification
accuracy of the previously derived signatures for discriminating
controls from AD patients using the 12 month data. Of the
participants used in the baseline analysis described above, 12
month data were available for 50 controls and 97 AD patients
(individuals who had converted to AD in the period between
baseline and 12 month evaluations were not included in this
analysis). These signatures performed better on 12 month data
than the signatures for discriminating controls from MCI
progressors discussed in the preceding paragraph, returning
sensitivity and specificity values comparable to those achieved
with baseline data (Table 8).
Using the change in analyte concentration over time as a
biomarker
We hypothesized that better accuracy in discriminating controls
and MCI progressors might be achieved by assessing the change in
analyte levels within individual participants over time. Longitudi-
nal analyses of this kind essentially provide an internal control for
non-disease-related variation by normalizing baseline values across
Table 8. Validation of proposed signatures on data collected
at 12 month follow-up.
Signature Sens Spec MCC
Control v MCI Progressor – Single Analyte Signature
Signature with APOE
aFull set of samples 79.3 56.2 0.36
bSize-matched groups 65.8 70.8 0.37
Signature without APOE
aFull set of samples 79.1 37.0 0.18
bSize-matched groups 57.4 49.6 0.07
Control v MCI Progressor – Pair-Wise Differences Signature
Signature with APOE
aFull set of samples 71.7 45.4 0.17
bSize-matched groups 58.2 59.8 0.18
Signature without APOE
aFull set of samples 81.2 42.8 0.27
bSize-matched groups 66.2 59.4 0.26
Control v AD – Single Analyte Signature
Signature with APOE
cFull set of samples 81.9 68.6 0.51
dSize-matched groups 72.8 81.4 0.55
Signature without APOE
cFull set of samples 79.4 55.6 0.37
dSize-matched groups 61.6 69.6 0.32
aThe full set of samples contained data on 50 Controls and 92 MCI Progressors.
bThe size-matched groups contained data on 50 Controls and 50 MCI
Progressors.
cThe full set of samples contained data on 50 Controls and 97 AD patients.
dThe size-matched groups contained data on 50 Controls and 50 AD patients.
doi:10.1371/journal.pone.0034341.t008
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gender and genotype, which may affect cross-sectional data.
To address this hypothesis, we calculated the change in analyte
concentration from baseline to 12 months follow-up. For log10-
transformed data, this was calculated by subtracting the baseline
value from the 12 month value. For raw data, this was calculated
by dividing the 12 month concentration by the baseline
concentration. In order to eliminate from consideration analytes
showing non-AD related variation, we excluded any analyte that
changed on average more than 20% from baseline to 12 months in
individuals from the Control group, leaving 110 analytes.
Data were then entropy filtered and feature set analysis
performed as described above. Of the 110 analytes assessed, 26
passed the entropy filter. The smallest signature that produced a
solution (i.e. a=1, b=1) to the feature set problem contained
eight analytes (Table 9). (While the APOE analyte passed the
entropy filter, it was not present in this signature and therefore did
not need to be excluded from consideration as it was in previous
analyses). In classifying controls and MCI progressors, the
signature from this longitudinal analysis gave higher values of
sensitivity and specificity than the corresponding signatures
generated from cross-sectional data. When tested on the full set
of samples (50 controls, 92 MCI progressors), the signature
achieved a sensitivity of 88.2% and a specificity of 76.2%
(MCC=0.65). Testing on size-matched groups (50 controls, 50
MCI progressors) returned a sensitivity of 81.6% and a specificity
of 83.8% (MCC=0.66). However this signature did not effectively
discriminate progressors from non-progressors within the MCI
group (sensitivity=57.6%, specificity=48.0%).
Similarly, we generated a signature based on the change in
meta-feature values (pair-wise differences) over the 12 month
period. After restricting the dataset to meta-features that did not
show a substantial change from baseline to 12 months in
individuals from the Control group, the smallest signature that
produced a solution (i.e. a=1,b=1) contained five meta-features
(Table 9). When tested on the full set of samples (50 controls, 92
MCI progressors), the signature achieved a sensitivity of 94.0%
and a specificity of 87.4% (MCC=0.82). Testing on size-matched
groups (50 controls, 50 MCI progressors) returned a sensitivity of
89.2% and a specificity of 92.2 (MCC=0.82), yet this still failed to
improve discrimination within the MCI group (sensitivity=53.7%,
specificity=55.4%).
In addition, we directly compared longitudinal data from the
MCI Progressor and MCI Other groups using several approaches,
including both combinatorial optimization and conventional
statistics, but were still unable to identify either univariate or
multivariate markers that discriminate progressors from non-
progressors (data not shown).
In conclusion, we have identified signatures which are highly
effective in discriminating controls from MCI progressors or AD
patients but neither the cross-sectional nor longitudinal signatures
were able to effectively discriminate progressors from non-
progressors within the MCI group. This appears to relate to real
biological heterogeneity within the MCI group and not limitations
of any one particular feature selection method.
Discussion
In this independent analysis of the ADNI Plasma Proteome
dataset, we have demonstrated the value of a novel multivariate
feature selection approach for identifying signatures of plasma
analytes that distinguish pre-clinical AD from healthy controls
more effectively than a collection of the ‘best’ markers as
determined by statistical univariate analysis. The important
difference between this type of approach and other more
conventional analyses of putative blood biomarkers is that it
considers information about individual participants rather than
just assessing univariate measures of class central tendency and
variance. As a result, a signature set will sometimes contain
analytes that do not vary significantly between groups of control
and test samples yet still contribute to distinguishing these groups
through the contrast between their behaviour and that of other
analytes within individuals. This is not taken into consideration by
univariate approaches that assess the levels of single analytes in
isolation. In addition, particular analytes that do not vary
significantly between two large groups can sometimes provide
information about a subset of samples with profiles that are not
consistent with the majority of the sample pool. It is therefore
important to stress that the unitary components of a multivariate
signature should not be trialled as stand-alone univariate
biomarkers but instead need to be validated in the context of all
the analytes comprising that signature, using appropriate classifi-
cation algorithms.
The analytes that were measured by the ADNI study were not
all selected because of specific links with AD, however a number of
the analytes comprising the signatures we identified have been
shown previously to be altered in blood or CSF from people with
MCI or AD (Table S15). Notably, other studies have found a2-
macroglobulin levels to be higher in plasma from AD patients [33]
and transthyretin and transferrin levels to be lower in serum from
AD patients than controls [34,35], consistent with the findings
from the ADNI plasma dataset. While it is difficult to directly
compare the longitudinal and meta-feature analyses with the single
analyte comparisons previously reported in the literature, several
of the longitudinal signature components have also been
potentially implicated in AD through previous biomarker studies.
These include cystatin C, sortilin and kidney injury molecule 1,
Table 9. Feature set selection of signatures to discriminate
control and MCI progressor samples based on longitudinal
change.
a) Single Analyte Longitudinal Signature
Chemokine CC-4
Complement Factor H
Cystatin C
Interleukin-16
Kidney Injury Molecule 1
Macrophage Inflammatory Protein-1a
Resistin
Sortilin
b) Pair-Wise Differences Longitudinal Signature
Adiponectin & Complement Factor H
Cancer Antigen 19-9 & Macrophage Inflammatory Protein-1a
CD 40 antigen & Complement Factor H
Chemokine CC-4 & E-Selectin
Immunoglobulin A & Matrix Metalloproteinase-7
Signatures were generated using longitudinal data of the change in analyte
levels over 12 months on 50 Control and 92 MCI Progressor participants. a)
Signature generated when considering the change in individual analytes. b)
Signature generated when considering the change in values for pair-wise
difference metafeatures.
doi:10.1371/journal.pone.0034341.t009
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CSF samples [36], In addition, sortilin shows similarity to the
sortilin-related receptor SORL1 that is genetically associated with
AD risk [37,38]. It is noteworthy that the directions of the
longitudinal effects observed for these analytes in plasma appear
consistent with the directions of changes in AD patients relative to
controls in the ADNI CSF study discussed above.
It is striking that the majority of the analytes involved in the
longitudinal signatures have been highlighted in the literature as
important in renal disease in particular and, often in relation to
this, in cardiovascular disease or diabetes. Notable examples
include cystatin C, kidney injury molecule 1, cancer antigen 19-9,
complement factor H and macrophage inflammatory protein 1a.
However, while this suggests that differences relating to these
conditions may exist between controls and MCI progressors, not
all of the group differences were in directions that would normally
be associated with pathogenicity and some may instead reflect
compensatory mechanisms, complicating interpretation.
While there have been no published studies which have used the
ADNI plasma dataset to identify signatures that distinguish
controls from MCI progressors, one recently published study by
O’Bryant and colleagues used the ADNI dataset to test the
classification accuracy of a signature designed to discriminate
cognitively normal controls from patients with clinical AD [39].
This signature, which was selected based on serum biomarker data
from the Texas Alzheimer’s Research Consortium, returned a
sensitivity of 54% and specificity of 78% when tested on baseline
ADNI data. The authors reported that as seen in other studies,
accuracy was improved substantially by incorporating demo-
graphic and clinical lab data. Similar to our signatures for
discriminating controls and AD patients, the signature of O’Bryant
and colleagues comprised a total of 11 analytes, however only one
of the analytes in this signature (tenascin C) passed the entropy
filter used in our analyses. While we have not conducted a detailed
analysis of how the multitude of clinical and demographic
variables collected by ADNI can be combined with plasma
protein data to generate signatures with improved classification
accuracy, this is likely to be an important direction for future
analyses.
We have previously applied our analysis approach to the plasma
proteomic dataset contributed by Ray and colleagues [9], refining
their 18-protein biomarker signature for distinguishing controls
from AD patients to a 5-protein signature [10]. However, as
described above, there are inconsistencies between the ADNI
dataset and the dataset of Ray and colleagues. This discrepancy
may reflect differences in the participant cohort, differences in the
sensitivity of the assays used by the two studies, differences in the
selection of thresholds to eliminate background noise or other
factors. The Luminex technology used in the ADNI study has
been well validated and the assay protocols include stringent
quality controls, measurement of standards to allow calculation of
the absolute concentration of plasma analytes and calculation of
the least detectable dose (LDD) to facilitate identification of
unreliably low readings. Further assessment of these different
techniques is required to explain the discrepancies.
In addition, the study by Ray and colleagues did not assess
APOE genotype. Our analyses show that APOE genotype has
important effects on plasma levels of APOE and possibly other
biomarkers. The finding that levels of APOE in the plasma are
affected by APOE genotype is consistent with previous studies,
which have demonstrated a gradient of APOE plasma concentra-
tions as a function of APOE genotype (e2.e3.e4) [40–43]. It is
well established that plasma concentrations of total cholesterol and
low density lipoprotein cholesterol also differ considerably
depending on APOE genotype [44–48] and it is feasible that levels
of various plasma proteins are regulated in response to changes in
cholesterol or APOE levels. In support of this, APOE genotype has
previously been associated with changes in blood levels of
apolipoprotein A [49], apolipoprotein B [44,45,48,49] and C-
reactive protein [50,51]. The effect of APOE genotype on the
putative plasma biomarkers explored here highlights the impor-
tance of first considering an individual’s APOE genotype if a
plasma biomarker panel is to be used as a diagnostic tool. It may
even be necessary to test different biomarker signatures depending
on APOE genotype, particularly in view of the variability in
frequencies of different APOE alleles across different populations
[52,53].
While the effect of APOE genotype on plasma APOE
concentration observed here was independent of clinical diagnosis,
it is nonetheless possible that plasma APOE levels are still relevant
to AD pathogenesis. Various studies have demonstrated that APOE
genotype can influence brain Ab levels (with APOE-e4 carriers
having greater Ab deposition than non-carriers) [54–58] but few
have investigated how this relates to plasma APOE levels.
Consistent with the various studies just mentioned [54–58], one
paper on the relationship between APOE genotype, brain Ab
deposition and plasma APOE concentration in non-demented
individuals [59] reported higher Ab burden in the medial temporal
cortex of APOE-e4 carriers than non-carriers, as assessed by
Pittsburgh Compound B retention [59]. However it also reported
a positive correlation between plasma APOE concentration and
brain Ab burden, with higher plasma APOE levels in APOE-e4
carriers (n=10) relative to non-carriers (n=29) as measured by
ELISA [59]. This is not consistent with several other studies of the
relationship between plasma APOE levels and APOE genotype
[40–43] or with our findings in the ADNI cohort. This indicates
the need for further research into the relationship between plasma
APOE and events in the brain.
Plasma levels of APOE and other proteins may also provide
insights into vasculopathy in particular individuals. This may be
informative as co-existing vasculopathy can affect AD onset and
progression. In this context it is interesting to note that serum
glutamic oxaloacetic transaminase, which we identified in
signatures discriminating controls from both MCI progressors
and AD patients, has been proposed as a predictive biomarker for
functional outcome following ischemic stroke [60].
In addition, we cannot exclude the possibility that common
polymorphisms in genes other than APOE may also affect plasma
levels of their corresponding protein or other proteins – this will
require further investigation by an integrated analysis of genomic
and proteomic data. There could also be effects on levels of plasma
proteins due to diet or factors, for example systemic inflammation,
which may be affected in various conditions common in older
people (e.g. diabetes, heart disease, cancer and arthritis). Such
effects may partly account for the large number of inflammatory
markers (e.g. interleukins) that were identified in the 18-protein
signature of Ray and colleagues but were either not altered or not
detectable in the ADNI study.
Another factor that may affect interpretation of the ADNI
proteomics data is that, as noted in the ADNI Data Primer, the
control samples chosen for proteomic studies were subject to
selection bias. Samples selected for inclusion had baseline CSF
Ab42 levels above the median baseline CSF Ab42 levels of the
control cohort. This led to an abnormally low frequency of the
APOE-e4 allele, presumably due to an association between APOE
genotype and CSF Ab42 levels. While this is an appropriate
strategy for improving detectability of differences between the
controls and the disease groups, it may have other unanticipated
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above. In addition, the disparity in APOE-e4 frequency is likely to
have led to an overestimation of the ability of APOE genotype,
alone or in combination with demographic variables such as age
and gender, to distinguish the clinical groups.
Differences in the size of the participant groups had a profound
influence on the values for sensitivity and specificity determined by
the classification algorithms. This probably occurs because most
classifiers use a training protocol that involves optimizing
classification strategies to achieve maximal values for total
prediction accuracy. This leads to a bias towards strategies that
correctly classify the group with the larger sample size, as this
group will constitute a higher proportion of the total sample and
will therefore return higher values for total prediction accuracy
when called correctly. This highlights one limitation of the plasma
analyte dataset currently available for ADNI, which contains
considerably fewer control samples than MCI or AD.
Classification strategies that favor sensitivity over specificity are
unlikely to be desirable in a clinical diagnostic setting, where it is
important to avoid giving healthy people the false impression that
they have a terminal disease with no effective treatment. We
anticipate that the clinical applicability of the signatures will
improve as data become available for larger numbers of
cognitively normal controls that are more representative of the
general population, allowing more appropriate classification
strategies to be selected. Until further control data become
available, an alternative approach might be to manually tune
classification strategies, based on approaches derived from receiver
operating characteristic (ROC) curve analysis, to make specificity a
high priority in addition to sensitivity.
The consideration of meta-features representing pair-wise
differences generally led to biomarker signatures with improved
prediction accuracy relative to signatures comprising single
analytes. This may be due to the identification of two analytes
that are mathematically or biologically synergistic with regard to
disease prediction capacity, the mitigation of confounding effects
that arise from inter-sample biological variability or technical
variability, or a combination of these factors. The lower accuracy
of signatures comprising pair-wise sums probably arises because
calculating the sum of Z-score values of log10-transformed data
(comparable to calculating the product of the relative abundance
of two analytes) will compound any effects of variability rather
than mitigate them.
The meta-feature signatures (Table 5) might also help identify
protein interactions of possible biological relevance, as some of the
meta-features selected by our method comprise analytes with
related molecular functions. Examples of pairs which are
potentially related include the chemokine meta-feature pair
macrophage inflammatory protein-1a (CCL3) and pulmonary
and activation-regulated chemokine (CCL18) and the matrix
metalloproteinase-9 and -10 pair. In any event, the improvement
in classification accuracy using meta-features demonstrates that
the consideration of meta-features represents a useful tool in the
search for biomarkers.
While the various signatures proposed here provided accurate
classification when considered in the context of the baseline
dataset from which they were identified, some performed poorly
when tested on data collected at 12 month follow-up. This was
particularly true of signatures designed to discriminate controls
from individuals with pre-clinical AD (here used to mean
individuals with MCI who later progress to AD), in contrast to
the signatures designed to discriminate controls from individuals
with existing AD, which performed well at both time points. The
reasons for this are uncertain. One possible explanation is that if
plasma protein profiles reflect the extent of disease progression, it
would be expected that protein profiles of controls and AD
patients differ more than those of controls and individuals with
MCI. As a result, the AD group, being further separated from
controls, might be expected to be relatively more robust than the
MCI group against fluctuations in plasma analyte levels for any
reason.
The ADNI proteomics data that are currently available only
cover two time points 12 months apart, a period that may be of
insufficient duration to detect substantial clinical or proteomic
differences. It would be informative to be able to test our proposed
signatures across a wider range of time points if data become
available.
Nonetheless, the most accurate classification results we obtained
came from signatures that considered the longitudinal change in
analyte levels or meta-feature values over the 12 month period.
While assessing changes within individuals over time is less
convenient than a single test, the stronger performance of a
signature based on longitudinal changes suggests that this is an
avenue that should be explored in order to improve predictive
accuracy.
It was interesting to note the lack of biomarkers that could
reliably distinguish individuals with MCI who have progressed to
AD from those who have not yet progressed. This is likely to be at
least partly due to a high degree of heterogeneity among the non-
progressor group. Some might progress to AD in subsequent years,
while others may progress to different neurodegenerative condi-
tions. It is also likely that a number of these individuals will remain
with only MCI or even revert to control status. It will be important
to determine whether the signatures proposed here have the ability
to predict which of these individuals will later convert to AD, and
we look forward to the outcomes of follow up clinical evaluations.
In addition to unknown endpoints within the MCI group,
accurate biomarker identification might also be affected by
incorrect ascertainment of AD or co-existing pathologies. As a
definitive diagnosis of AD cannot be made until brain pathology is
assessed post-mortem, a number of study participants with a
clinical diagnosis of AD may have dementias of other etiologies.
The extent of co-existing pathologies such as cerebrovasculopathy
is also best assessed post-mortem. It will only be possible to select
signatures with optimal accuracy for identifying pre-clinical and
clinical AD through the use of retrospective analyses after post-
mortem pathology has been assessed.
In addition, heterogeneity within the participant groups may
also stem from other disease co-morbidities. For example, as noted
above, the signatures obtained when considering the longitudinal
change from baseline to 12 months follow-up (for both single
analytes and meta-features) highlighted a number of analytes that
have been reported to have associations with renal failure, heart
failure or the metabolic syndrome and diabetes, all of which have
been associated with cognitive impairment or AD risk. These
conditions are common in older people and may lead to altered
plasma protein profiles and a high degree of analyte variation
within the participant groups. The classification accuracy of
signatures might therefore be improved by first taking into account
co-morbidities.
The analyses presented here highlight that in order to identify
reliable biomarkers, several factors need to be taken into account.
Biomarkers should be robust against age, gender and genotype. In
addition, a reliable biomarker should demonstrate minimal
variation unrelated to the disease of interest and measurements
should not fluctuate substantially between different time points in
healthy individuals. These factors may be affected by some of the
limitations of the current dataset. For example, as mentioned
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so may not accurately represent the parent population. In
addition, the Luminex analyte panel used was not designed
specifically for AD and better plasma biomarker signatures might
be achievable with the measurement of additional components,
whether other proteins or non-protein factors such as Ab, lipids
and metals. For example, for CSF biomarkers, combining novel
analytes identified using a Luminex proteomics assay with
established CSF biomarkers such as Ab and tau has been shown
to substantially improve accuracy in discriminating controls from
AD patients [4]. Similar approaches should also be effective with
plasma biomarkers. More accurate (although more expensive)
diagnostic classification might also be achieved through an
integrative approach combining blood and CSF proteomics,
genomics and brain imaging.
In conclusion, the findings of this study suggest that sets of
plasma analytes can act as useful biomarkers for pre-clinical AD
but can be influenced by a number of confounding variables, in
particular APOE genotype. More research is required on larger
samples which allow stratification by potential co-variates while
retaining sufficient power for analyses of subgroups. It is likely that
plasma biomarkers of the future will involve sets of analytes rather
than individual analytes and that accurate pre-clinical diagnosis
might require panels of multiple biomarkers. With technological
advances in multiplexing protein assays, financial considerations
relating to measuring large biomarker panels are becoming less of
a barrier to implementation and more importance will instead be
placed on assembling optimal panels rather than minimizing the
number of proteins.
Furthermore, if costs continue to come down, it may become
feasible to perform routine measurements of panels of plasma
analytes in ‘at risk’ individuals and monitor the change over time,
as is currently done in clinical biochemistry for various markers of
health and disease. In addition to providing a cost-effective and
minimally-invasive test capable of diagnosing AD in its pre-clinical
stages, these approaches may allow us to identify molecular
signposts of disease progression, improving understanding of the
disease course and facilitating the monitoring of changes over time
and responses to interventions.
Supporting Information
Figure S1 Heat maps based on the 11-analyte signature
generated when (A) including APOE and (B) excluding
APOE. For each analyte in the signature, Z-scores were calculated
for all control (n=54) and MCI progressor (n=163) participants.
A matrix containing the Z-score values was constructed and rows
and columns ordered by similarity, based on the correlation
distance, using a Memetic Algorithm (Methods). The output is
presented here as a heat map, where samples and analytes with
similar ‘expression profiles’ are clustered together. Green indicates
lower expression, red indicates higher expression. The bar below
the heat map indicates sample class (green – Control; blue – MCI
Progressor). Analyte abbreviations are given in Table 3.
(TIF)
Figure S2 Heat map based on the 6-protein signature
generated for APOE-e3 homozygotes. The bar below the
heat map indicates sample class (green – Control, n=34; blue –
MCI Progressor, n=50). Analyte abbreviations are given in
Table 3 and Table S6.
(TIF)
Figure S3 Heat maps based on differences of analyte
pairs comprising the signatures generated when (A)
including APOE and (B) excluding APOE. The bar below
the heat map indicates sample class (green – Control, n=54; blue
– MCI Progressor, n=163). Meta-feature abbreviations are given
in Table 5.
(TIF)
Figure S4 Heat maps based on sums of analyte pairs
comprising the signatures generated when (A) including
APOE and (B) excluding APOE. The bar below the heat map
indicates sample class (green – Control, n=54; blue – MCI
Progressor, n=163). Meta-feature abbreviations are given in
Table S8.
(TIF)
Figure S5 Heat maps based on relative levels of
analytes comprising the signature discriminating con-
trols from AD, generated when (A) including APOE and
(B) excluding APOE. The bar below the heat map indicates
sample class (green – control, n=54; blue – AD, n=112). Analyte
abbreviations are given in Table S11.
(TIF)
Table S1 Set of 10 classifiers used in this study. * Not used for
assessment of raw data due to poor performance.
(DOC)
Table S2 Definition of protein abbreviations used in Figure 2.
(DOC)
Table S3 Statistical univariate comparison of plasma analyte
levels in Control and MCI Progressor samples. Table lists all
analytes that differ significantly (p,0.01) in log10 concentration
between controls and MCI progressors. Control n=54, MCI
Progressor n=163.
(DOC)
Table S4 The 11 analytes that pass the entropy filter when
considering sized-matched groups of controls and MCI progres-
sors. * Not selected in either of the 11-analyte signatures generated
when considering the full set of samples (Table 3). { Analytes that
passed the entropy filter but did not show statistically significant
(p,0.01) differences between controls and MCI progressors (Table
S3). Control n=54, MCI Progressor n=54.
(DOC)
Table S5 Accuracy of analyte signatures from size-matched
groups in classifying controls and MCI progressors. Size-matched
groups contained 54 controls and 54 MCI progressors. *Sensitivity
of the signatures was assessed using a ‘test set’ comprising the
remaining 109 MCI progressors.
(DOC)
Table S6 Effect of age and gender on classification accuracy.
Size-matched groups were stratified by gender or age (n=27 per
group). The Control v MCI Progressor signature was assessed
using 10-fold cross-validation.
(DOC)
Table S7 6-analyte signature to discriminate Control and MCI
Progressor samples when considering on APOE-e3 homozygous
genotypes. Signature was generated using baseline data on the 34
controls and 54 MCI progressors that were homozygous for the
APOE-e3 genotype. Italicized analytes were selected in both of the
11-analyte signatures generated from unstratified data (Table 3).
(DOC)
Table S8 Comparison of meta-feature signatures with equally-
sized signatures comprising single analytes.
a The full set of
samples contained data on 54 controls and 163 MCI progressors.
b
The size-matched groups contained data on 54 controls and 54
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for cross-validation, whereas training and test sets were created by
dividing datasets into two equal subsets.
(DOC)
Table S9 Minimal meta-feature set selection of sums of analyte
abundances to discriminate Control and MCI Progressor samples.
Signatures were generated using baseline data on 54 controls and
163 MCI progressors. Italicized metafeatures contain at least one
analyte identified in the corresponding signature generated by
single analyte analysis (Table 3).
(DOC)
Table S10 Accuracy of meta-feature signatures involving sums
of analyte abundances in classifying controls and MCI progressors.
a The full set of samples contained data on 54 controls and 163
MCI progressors.
b The size-matched groups contained data on 54
controls and 54 MCI progressors. For each of these datasets, all
samples were used for cross-validation, whereas training and test
sets were created by dividing datasets into two equal subsets.
(DOC)
Table S11 Statistical univariate comparison of plasma analyte
levels in Control and AD samples. Table lists all analytes that differ
significantly (p,0.01) in log10 concentration between controls and
AD patients. *Raw data for placenta growth factor were normally
distributed and therefore did not require log10 transformation –
summary statistics of raw data for placenta growth factor are
presented in this table. Control n=54, AD n=112.
(DOC)
Table S12 Feature set selection of signatures* to discriminate
Control and AD samples. Signatures were generated using
baseline data on 54 controls and 112 AD patients. Italicized
analytes were identified in the corresponding signature that best
discriminated controls from MCI progressors (Table 3). *Follow-
ing initial entropy filtering there were several control and AD
samples that had the same discretization pattern (i.e. the discrete
values across the 13 analytes were identical in a control sample
and AD sample – this precludes a solution to the (a,b)-k-Feature Set
problem). To circumvent this problem for the purpose of generating
a solution, the dataset was pruned to remove these samples.
Following dataset pruning, 17 analytes passed the entropy filter.
These 17 analytes were used to generate the signatures in the
table. The pruned samples were incorporated back into the dataset
for assessment of classification accuracy.
(DOC)
Table S13 Accuracy of analyte signatures in classifying controls
and AD patients.
a The full set of samples contained data on 54
controls and 112 AD patients.
b The size-matched groups
contained data on 54 controls and 54 AD patients. *Sensitivity
of the signatures was assessed using a ‘test set’ comprising the
remaining 58 AD patients.
(DOC)
Table S14 Statistical univariate comparison of plasma analyte
levels in MCI Progressor and MCI Other samples. Table lists all
analytes that differ significantly (p,0.05) in log10 concentration
between MCI Progressor and MCI Other groups. MCI Progressor
n=163, MCI Other n=233.
(DOC)
Table S15 Previous evidence for altered levels of relevant
analytes in the context of AD. The table lists the analytes
comprising our 11-analyte signatures (Table 3) that have been
investigated in the context of MCI or AD. Unless otherwise stated,
the referenced studies of plasma/serum or CSF were consistent
with the findings in the ADNI plasma samples. Where findings are
inconsistent or a literature search returned no information on
levels of particular analytes in plasma/serum or CSF, additional
indirect evidence has been cited where available from studies of
AD brain or other tissues. To our knowledge, the proteins heparin-
binding EGF-like growth factor, betacellulin, brain natriuretic
peptide and CD5 have not been investigated in the context of AD.
(DOC)
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